ATOX1 and acute myeloid leukemia: In conclusion, the demethylase ALKBH5 downregulates ATOX1 by reducing its m6A levels, thereby modulating cuproptosis in AML-a mechanism that offers potential novel insights and therapeutic targets for AML treatment.<h4>Significance</h4>This study reveals that in AML, the demethylase ALKBH5 downregulates ATOX1 expression by reducing its m6A modification, thereby inhibiting cuproptosis and promoting AML progression.